PUBLISHER: Lucintel | PRODUCT CODE: 1416322
PUBLISHER: Lucintel | PRODUCT CODE: 1416322
Radioligand Therapy Trends and Forecast
The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.
A more than 150-page report is developed to help in your business decisions.
Radioligand Therapy by Segment
The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.
Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of Radioligand Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-
Radioligand Therapy Market Insights
Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.
North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Features of the Global Radioligand Therapy Market
Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).
Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the radioligand therapy market size?
Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.
Q2. What is the growth forecast for radioligand therapy market?
Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the radioligand therapy market?
Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.
Q4. What are the major segments for radioligand therapy market?
Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.
Q5. Who are the key radioligand therapy market companies?
Answer: Some of the key radioligand therapy companies are as follows:
Q6. Which radioligand therapy market segment will be the largest in future?
Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.
Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.